OncoMatch/Clinical Trials/NCT03805022
Benefit of Intensified Peri-operative Chemotherapy Within High-risk CINSARC Patients With Resectable Soft-tissue Sarcomas
Is NCT03805022 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments for non-metastatic soft-tissue sarcoma.
Treatment: Doxorubicin · Ifosfamide or dacarbazine · Doxorubicin · Ifosfamide or dacarbazine · At the discretion of the investigator — The primary objective of this trial is to investigate whether the addition of 3 additional neo-adjuvant cycles of chemotherapy (doxorubicin based chemotherapy) to standard management according to the ISG-STS 10-01 study (3 cycles of neoadjuvant doxorubicin based chemotherapy + surgery +/- radiotherapy) improves the outcome of high-risk CINSARC patients with resectable soft-tissue sarcoma (STS). Primary endpoint is metastatic progression-free survival (M-PFS, after 3 years of follow-up).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Sarcoma
Disease stage
Grade: 23 (fnclcc)
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: anthracycline-based chemotherapy
Exception: no more than two cycles of neo-adjuvant anthracycline-based chemotherapy before randomization
No more than two cycle of neo-adjuvant anthracycline-based chemotherapy before randomization
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT03805022 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages